Relief Therapeutics to End SEC Reporting Obligations with Form 15F Filing

Relief Therapeutics Holding SA has announced its intention to file Form 15F with the U.S. Securities and Exchange Commission (SEC) to terminate its SEC reporting obligations. This move will end the registration of its ordinary shares under Section 12(g) of the Securities Exchange Act and the associated reporting requirements under Section 15(d). Despite this change, the company will maintain its presence on the SIX Swiss Exchange and continue its ADR program, ensuring its shares remain quoted on the U.S. OTCQB market.

Upon the filing of Form 15F, Relief plans to suspend its SEC reporting obligations immediately, with full termination expected within 90 days. The decision aligns with Relief's strategic goal to reduce compliance costs and maintain operational flexibility. If a significant business transaction emerges, the company may consider reapplying for a regulated U.S. exchange listing in the future.